<DOC>
	<DOCNO>NCT00559221</DOCNO>
	<brief_summary>- To determine feasibility fludarabine cytarabine continuous infusion plus idarubicin granulocyte-colony stimulating factor prim patient resistant acute myeloid leukemia acute promyelocytic leukemia</brief_summary>
	<brief_title>FLAG+Ida With G-CSF Priming Patients Younger Than 60 Years With Resistant AML</brief_title>
	<detailed_description>- The feasibility evaluate term toxicity , complete remission rate , duration complete remission , disease-free survival , overall survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Failure achieve CR initial induction chemotherapy include standard dose cytarabine . Early relapse , occur first CR lasting le 12 month . Patients multiple relapse include . Written informed consent must give . 15 60 year age . 2 less ECOG performance scale . acute promyelocytic leukemia pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>AML</keyword>
</DOC>